Journal
DALTON TRANSACTIONS
Volume 49, Issue 45, Pages 16252-16267Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0dt01138j
Keywords
-
Categories
Funding
- FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, Brazil)
- CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil)
- CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)
- CNPq
- FAPEMIG (FundacAo de Amparo a Pesquisa do Estado de Minas Gerais)
- Universidad Nacional de Rosario [CUA-DAHZ 007/11]
- ANPCyT- FONCyT [PICT 2014-3704]
- Alexander von Humboldt Foundation [P4507]
- Max Planck Society [P10390]
- DFG [SFB1286]
- International Parkinson Fonds Deutschland
Ask authors/readers for more resources
Although normal aging presents an accumulation of copper and iron in the brain, this becomes more relevant in neurodegeneration. alpha-Synuclein (alpha-Syn) misfolding has long been linked with the development of Parkinson's disease (PD). Copper binding promotes aggregation of alpha-Syn, as well as generalized oxidative stress. In this sense, the use of therapies that target metal dyshomeostasis has been in focus in the past years. Metal-Protein Attenuating Compounds (MPACs) are moderate chelators that aim at disrupting specific, abnormal metal-protein interactions. Our research group has now established that N-acylhydrazones compose a set of truly encouraging MPACs for the bioinorganic management of metal-enhanced aggregopathies. In the present work, a novel ligand, namely 1-methyl-1H-imidazole-2-carboxaldehyde isonicotinoyl hydrazone (X1INH), is reported. We describe solution studies on the interaction and affinity of this compound for copper(ii) ions showing that a fine tuning of metal-affinity was achieved. A series of in vitro biophysical NMR experiments were performed in order to assess the X1INH ability to compete with alpha-Syn monomers for the binding of both copper(i) and copper(ii) ions, which are central in PD pathology. A preference for copper(i) has been observed. X1INH is less toxic to human neuroglioma (H4) cells in comparison to structure-related compounds. Finally, we show that treatment with X1INH results in a higher number of smaller, less compact inclusions in a well-established model of alpha-Syn aggregation. Thus, X1INH constitutes a promising MPAC for the treatment of Parkinson's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available